Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sulzermedica faces higher patent damages:

This article was originally published in Clinica

Executive Summary

Swiss medical device company Sulzermedica is facing higher patent infringement damages than expected if it loses its appeal. A court of first instance has set damages payable to Stryker (US) at $73 million, compared with original estimates of some $50 million. The news is contained in the third quarter results of Sulzer, Sulzermedica's engineering parent, which repeats earlier warnings that 1995 profits will be below last year's SwFr 195 million ($160 million). Sulzer's nine-month group sales were 2% up on the previous year at SwFr 4,252 million. Sulzermedica's turnover was 3% down at SwFr 769 million, which, nevertheless corresponds to a 13% increase when expressed in US dollars.

You may also be interested in...



Coronavirus Notebook: UK On Cusp Of First Vaccine Approval, Moderna To File mRNA-1273 in US & EU

Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.

Edgewell Finds COVID Bright Side: Wet Ones On Way To Becoming ‘Little Mega-Brand’

Skin hygiene is one of several categories where Edgewell Personal Care has a “right to win" after 18 months of renovations, according to the company’s 20 November Investor Day presentation. The firm has doubled its production capacity and has plans for a “full suite” of product innovation to build on Wet Ones’ 60% growth in fiscal 2020.

Stockwatch: The Post-Pandemic Dynamics Of Coronavirus Vaccines

Considerable value has been assigned to the companies developing coronavirus vaccines. Multiple suppliers and a met clinical need may erode much of that value after the pandemic.

Topics

UsernamePublicRestriction

Register

OM006145

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel